Research promising for cystic fibrosisMarch 19, 2008New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus Toronto, ON. - New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS). One of these compounds, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of chronic and acute bacterial respiratory infections in cystic fibrosis patients. Past studies have shown it is possible to prevent or delay the onset of certain chronic or deadly infections in cystic fibrosis patients with early antibiotic treatment. But the current availability of antibiotics against Pseudomonas aeruginosa, a pathogen that can cause urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, is limited and the pathogen shows signs of drug resistance. In an article published in the online edition of the journal PLoS Genetics, a team of investigators, including first author and U of T graduate student Anthony Arnoldo, identified several drugs that block a Pseudomonas aeruginosa toxin called ExoS. "These studies created a road map to the rational design of more potent, highly selective inhibitors against other similar toxins using a totally novel yeast-based approach," says lead author Stagljar. "This innovative approach is an important advance, not only for the value it may have in cystic fibrosis treatment, but also because this technique could be used to design novel therapies for any bacterial pathogen as well as the HIV virus." In the next phase of their research, Stagljar and his colleagues plan to test the action of their inhibitors in an animal model of cystic fibrosis. If successful, the therapeutics may provide an avenue for the treatment of this debilitating disease. University of Toronto |
|||||||||||||||||||||
| Related Cystic Fibrosis Current Events and Cystic Fibrosis News Articles Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Protein critical for insulin secretion may be contributor to diabetes A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes. New clinical guidelines for exacerbations in cystic fibrosis The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices. Nanoparticle treatment for burns curbs infection, reduces inflammation Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies. Research Matters at the Arizona Health Sciences Center (AHSC): UA Researchers Seek Safer Cystic Fibrosis Test Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers. Species diversity helps ASU researchers refine analyses of human gene mutations In the new era of personalized medicine, physicians hope to provide earlier diagnoses and improve therapy by evaluating patients' genetic blueprints. But, as a new bioinformatics study emphasizes, the first step must be to correctly decipher the deluge of information locked in our DNA and determine its impact on human health. New developments in reproductive medicine Three out of ten women who undergo polar body diagnosis go on to have a child. Faster, cheaper way to find disease genes in human genome passes initial test University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. Mutation responsible for cystic fibrosis also involved in muscle atrophy Patients with cystic fibrosis (CF) usually experience significant muscle loss, a symptom traditionally considered to be a secondary complication of the devastating genetic disease. More Cystic Fibrosis Current Events and Cystic Fibrosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||